ES12 (Glycadia Pharmaceuticals)

ES12 is a monoclonal antibody being developed by Glycadia Pharmaceuticals for the treatment of diabetic macrovascular disease. Glycadia is a clinical-stage biopharmaceutical company that focuses on developing therapeutics to address complications arising from diabetes, such as kidney, eye, and cardiovascular diseases. The company's research generally centers on the prevention and treatment of tissue damage caused by the nonenzymatic glycation of proteins and the accumulation of Amadori products. While ES12 is a key part of Glycadia's pipeline for macrovascular complications, specific details regarding its molecular target, precise mechanism of action, and current clinical trial phase have not been publicly disclosed.